The T3D Therapeutics Data Dispute
The first warning was that the results looked unusually good—especially for patients who had received a placebo. Others, supposedly taking an experimental Alzheimer’s pill, had no detectable drug in their blood. For the developer behind T3D-959, the prospect of a breakthrough was giving way to a different possibility: it could no longer trust its own trial.
A January 7 investigation in Science by journalist Charles Piller traced that conclusion to a July 2025 lawsuit filed by T3D Therapeutics. Its Phase 2 PIONEER study, begun in 2021, enrolled 250 people with mild to moderate Alzheimer’s disease to test a drug designed to improve the brain’s glucose metabolism. When the study ended in 2023, the company initially described encouraging signals. Later examinations, however, raised questions about whether some participants actually had Alzheimer’s. T3D characterized parts of the resulting records as “medically impossible.”
In court, T3D accused Clinilabs, the contract research organization paid $14.5 million to manage its study, of concealing widespread misconduct at five for-profit clinics in the Miami area. The clinics, it alleged, had financial incentives to maximize paid screenings and enrollments regardless of eligibility. T3D said excluding suspect data left too few reliable subjects to establish whether its candidate worked, effectively writing off a $35 million trial financed with public and private funds.
These remain allegations, not adjudicated findings. Clinilabs and the five clinics denied wrongdoing. The contractor argued that T3D had designed the study poorly and accused the company of making “demonstrable misrepresentations.” IMIC Medical Research, one of the clinics, also rejected the accusations. An unusually improving cognitive test score is not, by itself, proof of fabrication: individual assessments can fluctuate. The larger concern is the pattern across enrollment, drug exposure and medical records—and who can independently verify it.
The allegations sit within a broader pattern of disputed trial data. In 2023, BioVie reported excluding patients from 15 of 39 sites in its Alzheimer’s study after finding significant protocol deviations; its primary efficacy endpoint failed to reach statistical significance. In December 2025, Bristol Myers Squibb announced it would exclude data from a small number of sites in its Alzheimer’s-related psychosis trial and recruit additional participants. Bristol Myers did not allege the same fraud described by T3D.
Science also examined FDA inspection records identifying apparent errors at four of the five clinics named in T3D’s lawsuit during other trials, including questions about whether recruits met enrollment requirements.
Regulatory responsibility is distributed but not optional. Federal rules require sponsors to monitor clinical investigations, while contract researchers assuming those responsibilities are also accountable for them. As University of Pennsylvania medical ethicist Holly Fernandez Lynch told Science, failures can endanger participants and undermine confidence in research. Exactly what happened at the disputed clinics—and whether affected participants had been informed about concerns surrounding their records—remained unresolved.
The Volunteers Behind Contested Clinical Records
When a trial fails, a sponsor can exclude questionable records and recruit again. A volunteer cannot recover the months spent reporting symptoms, taking pills or waiting for answers. That asymmetry is particularly consequential in Alzheimer’s research, where cognitive decline may complicate informed consent and caregivers frequently participate in research decisions.
For some young adults, clinical research is already a deeply personal commitment. In a February 2025 article published by Washington University School of Medicine, Hannah Richardson, 24, described growing up with relatives participating in Alzheimer’s studies and witnessing her mother’s advocacy following her diagnosis. Speaking about her involvement in an entirely separate prevention trial, Richardson said, “I’ve always known I wanted to follow in her footsteps.”
Her experience illustrates the trust that research asks families to extend, sometimes across generations.
Yet young people do not approach clinical research with unconditional confidence. A 2025 study published in the Journal of Medical Internet Research conducted 16 focus groups involving 158 young adults. Participants generally recognized clinical trials’ social value but emphasized transparent information, personal autonomy and freedom from commercial influence as conditions for trusting research.
These perspectives reveal a tension often obscured by the language of scientific progress: researchers need participants to offer something profoundly personal—their bodies, time and vulnerability—yet those contributions eventually become entries in datasets participants may have little ability to inspect or challenge.
For a generation growing accustomed to AI-driven systems translating human experiences into data, the Miami allegations expose a distinction between collecting information and understanding its origins. Sophisticated analytical tools may detect inconsistencies, but they cannot independently guarantee that participants were properly screened, treatments correctly administered or consent meaningfully obtained.
The next medical breakthrough will likely arrive accompanied by an impressive graph. Before accepting what its curves promise, perhaps we should ask a less glamorous question: Who can account for every person behind the line?
Explore more exclusive insights at nextfin.ai.
